Actavis to Market Olanzapine in Germany
Iceland’s Actavis has launched olanzapine tablets, a treatment for schizophrenia and bipolar disorder, in Germany.
Olanzapine is the generic equivalent of Eli Lilly’s Zyprexa and will be available in 2.5-, 5-, 7.5-, 10-, 15- and 20-mg dose strengths.
Actavis’ third-party division, Medis, will sell the product to other pharmaceutical companies marketing it under their own labels.
The patent for Olanzapine is set to expire in most places in September 2011, but a German patent court ruled earlier this year that Eli Lilly’s patent is invalid, Actavis said.